Investment Thesis
Gossamer Bio exhibits severe financial distress with negative stockholders' equity of -$161.5M indicating technical insolvency. Collapsing revenues (-57.7% YoY to $17M) combined with $38.7M annual operating losses generate a runway of approximately 12-13 months at current cash levels, creating imminent solvency risk absent dramatic operational or capital structure improvements.
Strengths
- Maintains $41M cash balance providing short-term liquidity cushion
- Zero long-term debt reduces refinancing risk in near term
- Current and quick ratios of 2.20x provide surface-level short-term liquidity coverage
Risks
- Negative stockholders' equity of -$161.5M represents technical insolvency and balance sheet deterioration
- Revenue collapsed 57.7% YoY indicating severe business contraction or major partnership loss
- Operating cash burn of $38.7M annually with only $41M cash implies 12-13 month runway before capital exhaustion
- Net margin of -275.2% and operating margin of -264.6% demonstrate extreme unprofitability with no visible path to profitability
- Potential requirement for immediate capital raise, restructuring, or acquisition at severe equity dilution
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway projections
- Revenue stabilization and pipeline progression in biopharmaceutical development
- Strategic partnerships, licensing deals, or capital raise announcements
- Cost reduction initiatives and workforce adjustments
Financial Metrics
Revenue
17.0M
Net Income
-46.7M
EPS (Diluted)
$-0.20
Free Cash Flow
-38.7M
Total Assets
128.9M
Cash
41.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-264.6%
Net Margin
-275.2%
ROE
N/A
ROA
-36.2%
FCF Margin
-228.4%
Balance Sheet & Liquidity
Current Ratio
2.20x
Quick Ratio
2.20x
Debt/Equity
N/A
Debt/Assets
225.3%
Interest Coverage
-14.34x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:22:21.383150 |
Data as of: 2026-03-31 |
Powered by Claude AI